REal-world Data of CARdiometabolic ProtEcTion
ConditionCardiometabolic Diseases
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorSun Yat-sen University
About this trial
This study is a single-center, historical prospective cohort study including patients diagnosed with metabolic cardiovascular disease, including hypertension, diabetes, obesity, dyslipidemia, hyperuricemia. The primary outcome of the study is all-cause death and cardiovascular death, and the secondary outcome is major adverse cardiovascular events. We aim to measure associations of established or suspected cardiometabolic disease (CMD) risk factors and cardiovascular disease outcomes in a real-world representative cohort.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients over 18 years old;
Patients with clinical diagnosis of metabolic cardiovascular disease, including hypertension, diabetes, obesity, dyslipidemia, hyperuricemia.
Hypertension and normal high blood pressure: Three standardized blood pressure measurements in the clinic on different days, and all the blood pressure values of the three measurements were systolic blood pressure ≥ 120 mmHg and/or diastolic blood pressure ≥ 80 mmHg;
Diabetes: ① Typical symptoms of diabetes, and any of the following: ② Random blood glucose ≥ 11.1 mmol/L; ③ Fasting blood glucose (FPG) ≥ 7.0 mmol/L; ④ OGTT 2-hour postprandial blood glucose ≥ 11.1 mmol/L; ⑤ HbA1c ≥ 6.5%;
Disqualifiers
Patients unable to provide informed consent.
Trial population
Adult patients diagnosed with cardiometabolic diseases during hospitalization were enrolled.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
all-cause mortality
Death due to any cause after enrollment
Time frame
Through study completion, an average of 5 years2
Cardiovascular death
Death caused by cardiac causes
Time frame
Through study completion, an average of 5 yearsSecondary outcomes
1
Major adverse cardiovascular events
Including heart failure hospitalization, coronary heart disease, stroke, arrhythmia, valvular heart disease, etc.
Time frame
Through study completion, an average of 5 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov